Back

Use of new antidiabetic drugs in patients with cardiovascular diseases - real life data

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Real-world evidence on the cardiovascular effects of therapies for diabetes Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Jasna Vucak

Sukosan (Croatia)

8 More presentations in this session

Presentation thumbnail
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
Mr B. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
Doctor T. Guo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.
Doctor M. Feola (Mondovi, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry
thumbnail
Congress Presentation
A real-world data analysis investigating the cardioprotective effects of glucagon-like peptide-1 receptor agonists among people with type 2 diabetes in England

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources